Cutaneous Oncology News

The FDA approved relatlimab plus nivolumab for treatment of patients aged 12 years or older with unresectable or metastatic melanoma.

Relatlimab plus nivolumab continued to demonstrate a PFS benefit compared with nivolumab alone for patients with previously untreated metastatic or unresectable melanoma, according to a study presented during an ASCO Plenary Series session.

Among individuals who have undergone solid organ transplantation, viral infections and exposure to ultraviolet sunlight were associated with the highest risks for skin cancers, according to a study.

A phase 3 trial designed to assess the addition of bempegaldesleukin to nivolumab for previously untreated unresectable or metastatic melanoma failed to meet its primary endpoint, according to the agents’ manufacturers.

Poor differentiation and deep invasion are the most common risk factors for metastatic cutaneous squamous cell carcinoma following diameter and thickness, according to a study.

Merkel cell carcinoma has a recurrence rate of 40%, with 90% reoccurring within the first 3 years, according to a study.

Rare Disease Day is Feb. 28.

The use of artificial intelligence to triage and identify certain skin cancers had results similar to dermatologists’ identifications, according to a study.

The FDA placed a clinical hold on a phase 1 trial of LB1901, a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory T-cell lymphoma.

Acral lentiginous melanoma survival is less likely in patients from lower socioeconomic groups, as well as in Black or Hispanic white patients, according to a study.